Modulation by glucocorticoids of growth hormone secretion in patients with different pituitary tumors.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone), published as a clinical trial.

The acute administration of glucocorticoids is a new stimulus of growth hormone (GH) secretion in man.

Eight of them were normal controls, and 25 were patients with tumors affecting the hypothalamopituitary area.

Who Took Part

The study group was 33 subjects.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a placebo-controlled study.

Some subjects received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

What Was Measured

Dexamethasone administration to normal subjects did not alter GH levels in the first 2 h of the test.

Afterwards, a GH peak was observed around the third hour, GH levels returning to basal ones thereafter.

PubMed files the paper under topics including Acromegaly, Adenoma, Clonidine, Germinoma, Glucocorticoids, Growth Hormone and Growth Hormone-Releasing Hormone.

What This Means in Plain Language

The paper is a placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 33 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1993 (Neuroendocrinology), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.